Effects of 1-year treatment with fluvastatin or pravastatin on bone

This publication has 12 references indexed in Scilit:

• HMG-CoA Reductase Inhibitors and the Risk of Fractures
  JAMA, 2000
• Oral statins and increased bone-mineral density in postmenopausal women
  The Lancet, 2000
• Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
  The Lancet, 2000
• Fluvastatin, an HMG-CoA Reductase Inhibitor, Protects LDL from Oxidative Modification in Hypercholesterolemic Rabbits.
  Biological & Pharmaceutical Bulletin, 2000
• New insights into the pharmacodynamic and pharmacokinetic properties of statins
  Published by Elsevier ,1999
• Stimulation of Bone Formation in Vitro and in Rodents by Statins
  Science, 1999
• The Role of Geranylgeranylation in Bone Resorption and Its Suppression by Bisphosphonates in Fetal Bone Explants In Vitro: A Clue to the Mechanism of Action of Nitrogen-Containing Bisphosphonates
  Journal of Bone and Mineral Research, 1999
• Physiological Regulation of G Protein-Linked Signaling
  Physiological Reviews, 1999
• Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
  Proceedings of the National Academy of Sciences, 1999
• Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets
  British Journal of Clinical Pharmacology, 1997